Literature DB >> 20473586

Alternative splicing of the pituitary adenylate cyclase-activating polypetide (PACAP) receptor contributes to function of PACAP-27.

Mina Ushiyama1, Ryuji Ikeda, Morikatsu Yoshida, Kenji Mori, Kenji Kangawa, Hideki Sugawara, Kazuhiko Inoue, Katsushi Yamada, Atsuro Miyata.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP)-27 and PACAP-38 are neuropeptides performing a variety of physiological functions. The PACAP-specific receptor PAC1 has several variants that result mainly from alternative splicing in the mRNA region encoding the first extracellular (EC1) domain and the third intracellular cytoplasmic (IC3) loop. To characterize the molecular forms of alternative splicing variants of PAC1, we examined the binding affinity and activation of two major second messenger pathways (cAMP production and changes in [Ca(2+)]( i )) by PACAP-27. Activation of cAMP was influenced by the variant in both of the EC1 domain and IC3 loops. In the N form in the EC1 domain, the suppressive effect of the HOP1 form in the IC3 loop was enhanced. Regarding the intracellular calcium mobilization assay, the rank order of the potency of PACAP-27 for the different PAC1 isoforms was S/HOP1>>N/R~S/R>>N/HOP1. In particular, PACAP-27 exhibited remarkable potency of calcium mobilization in the S/HOP1-expressing cells at sub-picomolar concentrations even though the affinities of PACAP-27 to the four PAC1 isoforms were not significantly different. This suggests the specific functions of PACAP-27 due to PACAP-27 preferring PAC1 activation, and leads in clarification of the pleiotoropic function of PACAP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473586     DOI: 10.1007/s12031-010-9385-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  32 in total

1.  Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor.

Authors:  Steve Bourgault; David Vaudry; Isabelle Ségalas-Milazzo; Laure Guilhaudis; Alain Couvineau; Marc Laburthe; Hubert Vaudry; Alain Fournier
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

2.  Characterization of the PAC1 variants expressed in the mouse heart.

Authors:  Mina Ushiyama; Hideki Sugawara; Kazuhiko Inoue; Kenji Kangawa; Katsushi Yamada; Atsuro Miyata
Journal:  Ann N Y Acad Sci       Date:  2006-07       Impact factor: 5.691

3.  Structure of the human VIPR2 gene for vasoactive intestinal peptide receptor type 2.

Authors:  E M Lutz; S Shen; M Mackay; K West; A J Harmar
Journal:  FEBS Lett       Date:  1999-09-17       Impact factor: 4.124

4.  Differential activation of guinea pig intrinsic cardiac neurons by the PAC1 agonists maxadilan and pituitary adenylate cyclase-activating polypeptide 27 (PACAP27).

Authors:  Donald B Hoover; John D Tompkins; Rodney L Parsons
Journal:  J Pharmacol Exp Ther       Date:  2009-07-14       Impact factor: 4.030

5.  Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes.

Authors:  A Arimura; A Somogyvári-Vigh; A Miyata; K Mizuno; D H Coy; C Kitada
Journal:  Endocrinology       Date:  1991-11       Impact factor: 4.736

6.  Novel splice variants of type I pituitary adenylate cyclase-activating polypeptide receptor in frog exhibit altered adenylate cyclase stimulation and differential relative abundance.

Authors:  David Alexandre; Hubert Vaudry; Luca Grumolato; Valérie Turquier; Alain Fournier; Sylvie Jégou; Youssef Anouar
Journal:  Endocrinology       Date:  2002-07       Impact factor: 4.736

7.  Contractile and coronary vascular effects of pituitary adenylate cyclase activating polypeptide in neonatal pig hearts.

Authors:  R J Ascuitto; N T Ross-Ascuitto; A E Waddell; P J Kadowitz
Journal:  Cardiovasc Res       Date:  1996-02       Impact factor: 10.787

8.  Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide.

Authors:  P E Gottschall; I Tatsuno; A Miyata; A Arimura
Journal:  Endocrinology       Date:  1990-07       Impact factor: 4.736

9.  Differential intracellular signaling through PAC1 isoforms as a result of alternative splicing in the first extracellular domain and the third intracellular loop.

Authors:  Mina Ushiyama; Ryuji Ikeda; Hideki Sugawara; Morikatsu Yoshida; Kenji Mori; Kenji Kangawa; Kazuhiko Inoue; Katsushi Yamada; Atsuro Miyata
Journal:  Mol Pharmacol       Date:  2007-04-18       Impact factor: 4.436

10.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

Authors:  T Ishihara; R Shigemoto; K Mori; K Takahashi; S Nagata
Journal:  Neuron       Date:  1992-04       Impact factor: 17.173

View more
  9 in total

Review 1.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

2.  Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.

Authors:  Terry W Moody; Nauramy Osefo; Bernardo Nuche-Berenguer; Lisa Ridnour; David Wink; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2012-03-02       Impact factor: 4.030

Review 3.  VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies.

Authors:  Terry W Moody; Tetsuhide Ito; Nuramy Osefo; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-02       Impact factor: 3.243

Review 4.  Pleiotropic pituitary adenylate cyclase-activating polypeptide (PACAP): Novel insights into the role of PACAP in eating and drug intake.

Authors:  Andrew T Gargiulo; Genevieve R Curtis; Jessica R Barson
Journal:  Brain Res       Date:  2019-12-26       Impact factor: 3.252

5.  Intronic deletions of tva receptor gene decrease the susceptibility to infection by avian sarcoma and leukosis virus subgroup A.

Authors:  Weiguo Chen; Yang Liu; Hongxing Li; Shuang Chang; Dingming Shu; Huanmin Zhang; Feng Chen; Qingmei Xie
Journal:  Sci Rep       Date:  2015-04-15       Impact factor: 4.379

Review 6.  Signal Transduction by VIP and PACAP Receptors.

Authors:  Ingrid Langer; Jérôme Jeandriens; Alain Couvineau; Swapnil Sanmukh; Dorota Latek
Journal:  Biomedicines       Date:  2022-02-09

Review 7.  Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.

Authors:  Jessica Lu; Sarah J Piper; Peishen Zhao; Laurence J Miller; Denise Wootten; Patrick M Sexton
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

8.  Effects of pituitary adenylate cyclase-activating polypeptide isoforms in nucleus accumbens subregions on ethanol drinking.

Authors:  Andrew T Gargiulo; Breanne E Pirino; Genevieve R Curtis; Jessica R Barson
Journal:  Addict Biol       Date:  2020-10-05       Impact factor: 4.280

9.  Alternative Splicing of the Pituitary Adenylate Cyclase-Activating Polypeptide Receptor PAC1: Mechanisms of Fine Tuning of Brain Activity.

Authors:  Janna Blechman; Gil Levkowitz
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-21       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.